- Home
- CIEN vs BNTX Comparison
CIEN vs BNTX Comparison
Compare CIEN & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIEN | BNTX |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 24.8B |
| IPO Year | 1997 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CIEN | BNTX |
|---|---|---|
| Price | $200.42 | $96.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $152.36 | $137.40 |
| AVG Volume (30 Days) | ★ 3.5M | 1.3M |
| Earning Date | 12-11-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.32 | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $4,541,635,000.00 | $3,698,814,972.00 |
| Revenue This Year | $19.58 | $2.36 |
| Revenue Next Year | $16.89 | N/A |
| P/E Ratio | $205.91 | ★ N/A |
| Revenue Growth | ★ 12.97 | 3.70 |
| 52 Week Low | $49.21 | $81.20 |
| 52 Week High | $214.17 | $129.27 |
Technical Indicators
Market Signals| Indicator | CIEN | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 39.97 |
| Support Level | $186.39 | $95.61 |
| Resistance Level | $209.19 | $98.20 |
| Average True Range (ATR) | 10.53 | 2.93 |
| MACD | -0.80 | -0.51 |
| Stochastic Oscillator | 79.72 | 22.39 |
Price Performance
Historical ComparisonAbout CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.